PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review.
Immunotherapy
; 14(7): 577-592, 2022 05.
Article
de En
| MEDLINE
| ID: mdl-35373580
In this study, the authors found that the incidence of pericardial effusion and cardiac tamponade in non-small-cell lung cancer patients treated with PD-1/L1 inhibitors was 0.63% and 0.35%, respectively, and in chemotherapy was 0.07% and less than 0.01%, respectively. The authors found that PD-1/L1 inhibitors combined with chemotherapy did not increase the risk of cardiac adverse events (AEs); however, the risk of cardiac AEs with PD-1/L1 inhibitor monotherapy should be considered, and the damage of pembrolizumab to the pericardium needs further attention. The mechanism of pericardial effusion and cardiac tamponade is not well understood, and pseudoprogression cannot be ruled out. Although the incidence of cardiac AEs is low, the prevention and management of immunotherapy should be paid attention to.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Épanchement péricardique
/
Tamponnade cardiaque
/
Carcinome pulmonaire non à petites cellules
/
Tumeurs du poumon
Type d'étude:
Etiology_studies
/
Risk_factors_studies
/
Systematic_reviews
Limites:
Humans
Langue:
En
Journal:
Immunotherapy
Sujet du journal:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Année:
2022
Type de document:
Article
Pays d'affiliation:
Chine